<DOC>
	<DOCNO>NCT02770131</DOCNO>
	<brief_summary>Review clinical characteristic patient prescribed Repatha® treatment manage .</brief_summary>
	<brief_title>Chart Review Repatha® Subjects With Hyperlipidaemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Adults ( &gt; 18 year ) Provided informed consent Initiated Repatha® physician 's discretion , 1st August 2015 Received least one dose Repatha® Enrolled interventional study PCSK9 inhibitor within 12 week prior initiation Repatha®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>hypercholesterolaemia</keyword>
	<keyword>lipid-lowering therapy</keyword>
</DOC>